Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Security defenders are girding themselves in response to the disclosure of a maximum-severity vulnerability disclosed Wednesday in React Server, an open-source package that’s widely used by websites ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

TL;DR: Apple's upcoming M5 Pro and M5 Max processors feature a new chip design separating CPU and GPU blocks, enabling customizable core configurations. Built on TSMC's advanced 3nm N3P process with ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

As a small business owner, Liz understands the unique challenges entrepreneurs face. Well-versed in the digital landscape, she combines real-world experience in website design, building e-commerce ...

Get your jokes and your engines ready, because Max is once again HBO Max. The streaming service that's home to HBO content, Warner Bros. movies, all 10 seasons of "Friends" and a smattering of reality ...

The company announced the name change in May, and officially flipped the switch July 9. By Alex Weprin Senior Editor The name change, first announced onstage at WBD’s upfront presentation back in May, ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...